Assessment of cancer risk associated with 7-nitroso-3-(trifluoromethyl)-5,6,7,8-tetrahydro[1,2,4] triazolo-[4,3-a]pyrazine-contaminated sitagliptin use: A retrospective cohort study.
Takahiro SugiyamaTakashi FurunoYuichi IchinoseMasao IwagamiNoriko Ihana-SugiyamaKenjiro ImaiTamaki KakuwaRyoko RikitakeMitsuru OhsugiTakahiro HigashiHiroyasu IsoKohjiro UekiPublished in: Journal of diabetes investigation (2024)
We observed no evidence to suggest an increased cancer risk among patients prescribed NTTP-contaminated sitagliptin, although continued investigation is needed.